A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
2026年9月1日 更新者:Zelluna Immunotherapy AS
A Phase 1, Dose-Escalation, Open-Label Study, Evaluating the Safety and Tolerability of ZI-MA4-1, a TCR-NK Cell Therapy, in HLA-A*02:01 Positive Patients With Inoperable, Locally Advanced, or Metastatic MAGE-A4 Expressing Solid Malignancies
This study will recruit patients with the following cancer indications: ovarian cancer, squamous non-small cell lung cancer, synovial sarcoma and head and neck cancer, with inoperable locally advanced or metastatic solid tumours.
Currently, these patients have a poor prognosis and a relatively short overall survival.
There is a lack of meaningful, effective therapies available that improve the outcome for these patients.
The treatment being investigated in this study is ZIMA4-1, an allogeneic cell therapy product.
This is the first time ZI-MA4-1 will be administered to humans.
The study is planned to consist of two parts (A and B).
Part A includes up to four dose escalation cohorts and aims to identify the maximum tolerated dose of ZI-MA4-1 and give insight into the recommended Phase 2 dose (RP2D).
Part B consists of an expansion cohort and is designed to further evaluate the RP2D identified in Part A across one or more indications.
The study procedures and eligibility criteria will be the same for participants in Parts A and B, except for the dose level of ZI-MA4-1.
研究概览
研究类型
介入性
注册 (估计的)
9
阶段
- 阶段1
联系人和位置
本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。
学习联系方式
- 姓名:Zelluna Immunotherapy
- 电话号码:+47 413 80 080
- 邮箱:ctinfo@zelluna.com
学习地点
-
-
-
London、英国
- 招聘中
- The Royal Marsden NHS Foundation Trust
-
接触:
- Dr. Furness
-
Manchester、英国
- 招聘中
- The Christie NHS Foundation Trust
-
接触:
- Prof. Thistlethwaite
-
-
参与标准
研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。
资格标准
适合学习的年龄
- 成人
- 年长者
接受健康志愿者
不
描述
Inclusion Criteria:
- HLA-A*02:01 positive
- Tumour(s) show expression of the MAGE-A4 protein above a defined threshold
- Histopathological or cytological diagnosis of inoperable Locally Advanced or Metastatic malignant disease: ovarian cancer, squamous non-small cell lung cancer (NSCLC), synovial sarcoma or head and neck cancer.
- No approved therapy with demonstrated clinical benefit is indicated or available to treat the patient, or the patient is intolerant of or has refused standard of care therapy.
- Documented imaging confirmed disease progression while on or within 6 months after the end of the most recent therapy.
- Participant must have received ≥2 prior lines of cancer therapy except for patient with synovial sarcoma for whom ≥1 prior lines of cancer therapy.
- Measurable disease according to RECIST v1.1 criteria.
- ECOG performance status of 0 or 1 with no deterioration over the previous 2 weeks, and an anticipated life expectancy of >3 months
- Female participants are eligible to participate if they are not pregnant or breastfeeding. Woman of childbearing potential must have negative pregnancy test and agree to use an effective contraceptive method.
Other protocol defined inclusion criteria could apply.
Exclusion Criteria:
- Patients have received any prior cellular or gene therapy.
- Receiving experimental investigational products within 4 weeks of lymphodepletion.
- Recent therapies (within up to 4 weeks prior to lymphodepletion) including biologic agents (such as monoclonal antibodies), anti-cancer immunotherapy (such as monoclonal antibodies against PD-1 receptor or ligand).
- Residual toxicities ≥2 CTCAE grade due to prior therapy, that in the opinion of the investigator may interfere with study conduct.
- Any other active malignancy besides the tumour under study within 3 years prior to screening except for in situ removal of basal cell carcinoma or adequately treated cervix carcinoma in-situ.
- Active or documented history of autoimmune disease or any other diseases requiring immunosuppressive therapy or corticosteroid therapy. Physiological replacement, topical, and inhaled steroids are permitted.
- Significant CNS disorders.
- Myocardial infarction, cardiac angioplasty or stenting, cardiac arrhythmia requiring medication, unstable angina, New York Heart Association Class II or greater congestive heart failure, cardiac atrial or ventricular lymphoma involvement, or other clinically significant cardiac disease within 6 months of enrolment.
- Active fungal, bacterial viral, or other infection requiring intravenous antibiotic, antifungal, or antiviral medication within 7 days prior to lymphodepletion.
- Received or planned to receive a live vaccine ≤6 weeks before the planned start date of lymphodepletion.
- Severe or uncontrolled medical condition (e.g., severe chronic obstructive pulmonary disease, interstitial lung disease , severe Parkinson's disease, active inflammatory bowel disease) or psychiatric condition, which in the opinion of the investigator would interfere with study activities.
- Active bleeding diatheses, including but not limited to therapeutic anticoagulation, and treatment with major surgery within 28 days before lymphodepletion (minor surgical procedures such as lymph node biopsy/excision or catheter placement are permitted).
- Patients have significant immunosuppression
- Known significant hepatic or biliary abnormalities. Active infection with hepatitis B, hepatitis C.
- Any medical, psychological, or social condition, drug or alcohol abuse that would make it difficult for the patient to participate in the study and comply with the study procedures, restrictions, and requirements.
- History of allergic reactions to compounds chemically or biologically similar to cyclophosphamide, fludarabine or other agents used in the study
- QTc > 450 msec for male participants or > 470 msec for female participants
- Medical conditions, such as anti-coagulation, which is not suitable for reversal which, at the opinion of the investigator, preclude or make the patient a poor candidate for biopsy.
- Personal history of allergies or intolerance to local anaesthetic.
- Recent treatment with immunosuppressive agents
- Residual toxicities ≥2 Common Terminology Criteria for Adverse Events (CTCAE) grade due to prior therapy, that in the opinion of the investigator may interfere with study conduct Other protocol defined exclusion criteria could apply.
学习计划
本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:ZI-MA4-1 (TCR-NK cells)
Participants receive ZI-MA4-1 administered via IV infusion 3 times per treatment cycle at their assigned dose.
It is planned that all participants in the study will get a minimum of one treatment cycle and up to a maximum of two treatment cycles.
Prior to a treatment cycle, a participant is given fludarabine and cyclophosphamide to temporarily reduce lymphocytes in the body (lymphodepletion).
|
淋巴细胞化疗
淋巴细胞化疗
Allogeneic Natural Killer cells transduced with a T cell receptor targeting the tumour-specific melanoma-associated antigen 4 (MAGE-A4)
|
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Safety and tolerability of ZI-MA4-1
大体时间:From baseline through end of study visit (up to 5 years)
|
Assessed using clinical assessments and adverse event reporting, including dose-limiting toxicities (DLTs), treatment-emergent adverse events (TEAEs), and treatment-related adverse events (TRAEs)
|
From baseline through end of study visit (up to 5 years)
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
MTD and RP2D of ZI-MA4-1
大体时间:Through completion of study response follow-up (up to 2 years)
|
Identification of maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D) of ZI-MA4-1 based on observed DLTs and predefined dose-escalation rules
|
Through completion of study response follow-up (up to 2 years)
|
|
Long term safety
大体时间:Through end of study visit (up to 5 years)
|
Evaluate ZI-MA4-1 for the occurrence of delayed adverse events (AEs)
|
Through end of study visit (up to 5 years)
|
|
Minimum biologically active dose (MBAD) of ZI-MA4-1
大体时间:Through completion of study response follow-up (up to 2 years)
|
Assessment of preliminary anti-tumour activity
|
Through completion of study response follow-up (up to 2 years)
|
|
Objective Response Rate (ORR)
大体时间:Through completion of study response follow-up (up to 2 years)
|
Assessed by RECIST 1.1
|
Through completion of study response follow-up (up to 2 years)
|
|
Best Overall Response (BOR)
大体时间:Through completion of study response follow-up (up to 2 years)
|
Assessed by RECIST 1.1
|
Through completion of study response follow-up (up to 2 years)
|
|
Disease Control Rate (DCR)
大体时间:Through completion of study response follow-up (up to 2 years)
|
Assessed by RECIST 1.1
|
Through completion of study response follow-up (up to 2 years)
|
|
Pharmacokinetics of ZI-MA4-1
大体时间:3 years post-infusion of ZI-MA4-1
|
Evaluation of persistence of ZI-MA4-1 cells in the blood using vector copy number (VCN) analysis
|
3 years post-infusion of ZI-MA4-1
|
合作者和调查者
在这里您可以找到参与这项研究的人员和组织。
研究记录日期
这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。
研究主要日期
学习开始 (实际的)
2026年5月11日
初级完成 (估计的)
2028年12月1日
研究完成 (估计的)
2032年12月1日
研究注册日期
首次提交
2026年5月15日
首先提交符合 QC 标准的
2026年5月21日
首次发布 (实际的)
2026年5月29日
研究记录更新
最后更新发布 (实际的)
2026年9月4日
上次提交的符合 QC 标准的更新
2026年9月1日
最后验证
2026年9月1日
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- ZIMA-101
- ISRCTN14753723 (注册表标识符:ISRCTN registry)
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
未定
药物和器械信息、研究文件
研究美国 FDA 监管的药品
不
研究美国 FDA 监管的设备产品
不
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.